LILRB1-directed CAR-T cells for the treatment of hematological malignancies


Por: Marhelava, K, Fidyt, K, Pepek, M, Krawczyk, M, Forcados, C, Malinowska, A, Swiderska, B, Fernandez-Fuentes, N, Czerwik, N, Baranowska, I, Krzywdzinska, A, Sedek, L, Slota, L, Perkowski, B, Villatoro, A, Leray, T, Lech-Maranda, E, Menendez, P, Inderberg, EM, Wälchli, S, Winiarska, M and Firczuk, M

Publicada: 1 jun 2025 Ahead of Print: 1 abr 2025
Resumen:
CD19 CAR-T cells have established a new standard for relapsed/refractory B-cell malignancies. However, the treatment fails in 50% of patients, often due to CD19 antigen loss. Alternative immunotherapies targeting other antigens are being tested but show limited efficacy, especially in cases of lineage switching or loss of B-cell phenotype, highlighting the need for novel targets. Herein, we identified leukocyte-immunoglobulin-like-receptor-B1 (LILRB1, CD85j) as a novel target for CAR-T cells through cell surface proteomics on patient-derived samples of high-risk B-cell acute lymphoblastic leukemia (B-ALL). LILRB1, an immune inhibitory receptor, is normally expressed only on monocytes and B-cells. We observed stable LILRB1 expression in B-ALL and B-cell non-Hodgkin lymphoma (B-NHL), even after CD20/CD19-based immunotherapies. LILRB1 CAR-T cells showed antigen-specific antitumor activity in vitro against B-ALL/B-NHL cells, including those resistant to CD19 CAR-T-cells, and in vivo in B-ALL xenografts. Additionally, we identified LILRB1 in monocytic acute myeloid leukemia (AML) and demonstrated LILRB1 CAR-T cell cytotoxicity against AML cell lines in vitro and in vivo. These findings establish LILRB1 as a novel target for cancer immunotherapy and show evidence for the preclinical efficacy of LILRB1 CAR-T cells against haematological malignancies, including cases resistant to previous lines of immunotherapy, thus holding promise for further clinical development.

Filiaciones:
Marhelava, K:
 Polish Acad Sci, Dept Immunol, Mossakowski Med Res Inst, Warsaw, Poland

 Med Univ Warsaw, Dept Immunol, Warsaw, Poland

:
 Med Univ Warsaw, Dept Immunol, Warsaw, Poland

 Josep Carreras Leukemia Res Inst, Barcelona, Spain

Pepek, M:
 Med Univ Warsaw, Dept Immunol, Warsaw, Poland

Krawczyk, M:
 Polish Acad Sci, Dept Immunol, Mossakowski Med Res Inst, Warsaw, Poland

 Med Univ Warsaw, Dept Immunol, Warsaw, Poland

 Polish Acad Sci, Mossakowski Med Res Inst, Ctr Postgrad Med Educ, Doctoral Sch Translat Med, Warsaw, Poland

Forcados, C:
 Oslo Univ Hosp, Dept Oncol, Translat Res Unit, Sect Cellular Therapy, Oslo, Norway

 Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway

Malinowska, A:
 Polish Acad Sci, Inst Biochem & Biophys, Mass Spectrometry Lab, Warsaw, Poland

Swiderska, B:
 Polish Acad Sci, Inst Biochem & Biophys, Mass Spectrometry Lab, Warsaw, Poland

:
 Josep Carreras Leukemia Res Inst, Barcelona, Spain

Czerwik, N:
 Med Univ Warsaw, Dept Immunol, Warsaw, Poland

Baranowska, I:
 Polish Acad Sci, Dept Immunol, Mossakowski Med Res Inst, Warsaw, Poland

Krzywdzinska, A:
 Inst Hematol & Transfus Med, Lab Immunophenotyping, Warsaw, Poland

Sedek, L:
 Med Univ Silesia, Dept Microbiol & Immunol, Zabrze, Poland

Slota, L:
 Med Univ Silesia, Dept Pediat Hematol & Oncol, Zabrze, Poland

Perkowski, B:
 Med Univ Silesia, Dept Pediat Hematol & Oncol, Zabrze, Poland

Villatoro, A:
 Oslo Univ Hosp, Dept Oncol, Translat Res Unit, Sect Cellular Therapy, Oslo, Norway

Leray, T:
 Oslo Univ Hosp, Dept Oncol, Translat Res Unit, Sect Cellular Therapy, Oslo, Norway

 Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway

Lech-Maranda, E:
 Inst Hematol & Transfus Med, Dept Hematol, Warsaw, Poland

:
 Josep Carreras Leukemia Res Inst, Barcelona, Spain

 Inst Salud Carlos III, Ctr Invest Biomed Red Oncol, Madrid, Spain

 Inst Salud Carlos III, Red Espanola Terapias Avanzadas TERAV, Madrid, Spain

 Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain

 Univ Barcelona, Sch Med, Dept Biomed, Barcelona, Spain

 Inst Recerca Hosp, St Joan de Deu Pediat Canc Ctr Barcelona SJD PCCB, Barcelona, Spain

Inderberg, EM:
 Oslo Univ Hosp, Dept Oncol, Translat Res Unit, Sect Cellular Therapy, Oslo, Norway

Winiarska, M:
 Polish Acad Sci, Dept Immunol, Mossakowski Med Res Inst, Warsaw, Poland

 Med Univ Warsaw, Dept Immunol, Warsaw, Poland

Firczuk, M:
 Polish Acad Sci, Dept Immunol, Mossakowski Med Res Inst, Warsaw, Poland

 Med Univ Warsaw, Dept Immunol, Warsaw, Poland
ISSN: 08876924





Leukemia
Editorial
Nature Publishing Group, MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 39 Número: 6
Páginas: 1395-1411
WOS Id: 001459771000001
ID de PubMed: 40186066
imagen Green Accepted, Green Submitted, hybrid

MÉTRICAS